8 Literaturangaben

1. Van Geuns RJ, Wielopolski PA, de Bruin HG, et al. Basic principles of magnetic resonance imaging. Prog Cardiovasc Dis 1999; 42(2): 149-56.

2. Nagel E, van Rossum AC, Fleck E. Kardiovaskuläre Magnetresonanztomographie. Steinkopff Darmstadt 2002; 3-19.

3. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 2004; 25(21): 1940-65.

4. Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 2005; 45(11): 1815-22.

5. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109(10): 1250-8.

6. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108(1): 54-9.

7. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43(12): 2260-4.

8. Kelle S, Nagel E, Fleck E. Cardiovascular MR-replacement of diagnostic invasive coronary angiography?. Internist 2006; 47(1): 18-27.

9. Hombach V, Grege O, Botnar RM. Kardiovaskuläre Magnetresonanztomographie. Schattauer-Verlag 2005.

10. Smith HJ. Cardiac MR Imaging. Acta Radiol 1999; 40(1): 1-22.

11. Lanzer P, Barta C, Botvinick EH, et al. ECG-synchronized cardiac MR imaging: method and evaluation. Radiology 1985; 155(3): 681-6.

12. Nelson KL, Runge VM. Basic principles of MR contrast. Top Magn Reson Imaging 1995; 7(3): 124-36.

13. Brasch RC, Weinmann HJ, Wesbey GE. Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. Am J Roentgenol 1984; 142(3): 625-30.

14. Shellock FG, Kanal E. Safety of Magnetic Resonance Imaging contrast agents. J Mag Reson Imag 1999; 10: 477-484.

15. Niendorf HP, Alhassan A, Geens VR, Clauss W. Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications. Invest Radiol 1994; 29 Suppl 2: 179-82.

16. Haustein J, Niendorf HP, Krestin G, et al. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol 1992; 27(2): 153-6.

17. Schlosser T, Hunold P, Herborn CU, et al. Myocardial infarct: depiction with contrast-enhanced MR imaging--comparison of gadopentetate and gadobenate. Radiology 2005; 236(3): 1041-6.

18. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100(19): 1992-2002.

19. Saeed M, Wendland MF, Takehara Y, Higgins CB. Reversible and irreversible injury in the reperfused myocardium: differentiation with contrast material-enhanced MR imaging. Radiology 1990; 175(3): 633-7.

20. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Eng J Med 2000; 16: 1445-1453.

21. Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998; 97(18): 1802-9.

22. Laissy JP, Messin B, Varenne O, et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest 2002; 122(5): 1638-48.

23. Pennell DJ, Maceira AM, Joshi J, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111(2): 186-93.

24. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effect of steroid therapy by Gadolinium-DTPA enhanced magnetic resonance imaging. Am J Med 2001; 110(7): 520-527.

25. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45(10): 1683-90.

26. Schulz-Menger J, Wassmuth R, Abdel-Aty H, et al. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart 2006; 92(3): 399-400.

27. Mills JA: Systemic lupus erythematosus. N Engl J Med1999; 330(26): 1871-9.

28. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003; 56(7): 481-90.

29. Feletar M, Ibanez D, Urowitz MB, Gladman DD. The impact of the 1997 update of the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: what has been changed? Arthritis Rheum 2003 Jul; 48(7): 2067-9.

30. Tan EM, Cohen As, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.

31. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10(5): 541-7.

32. Roberts WC, High ST. The heart in systemic lupus erythematosus. Curr Probl Cardiol 1999; 24(1): 1-56.

33. Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus; Lupus 2005; 14(9): 683-6.

34. Krosch H, Schabitz J, Rikirsch P. Herzerkrankungen bei Kollagenosen. Z Gesamte Inn Med 1970; 25(10): 424-32.

35. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74(3): 275-84.

36. Sturfelt G, Eskilsson J, Nived O, et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients form a defined population. Medicine (Baltimore) 1992; 71(4): 216-23.

37. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343(19): 1388-98.

38. Lieberman EB, Hutchins GM, Herskowitz A, et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991; 18(7): 1617-26.

39. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999; 99(8): 1091-100.

40. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342(10): 690-5.

41. Lauer B, Niederau C, Kuhl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997; 30(5): 1354-9.

42. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 1997; 95(1): 163-8.

43. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1(1): 3-14.

44. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulaton 2006; 113:593-595.

45. Wojnicz R, Nowalany-Kozielska E, Wodniecki J, et al. Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Eur Heart J 1998; 19(10): 1564-72.

46. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975; 58(2): 243-64.

47. Fairfax MJ, Osborn TG, Williams GA, et al. Endomyocardial biopsy in patients with systemic lupus erythematosus. J Rheumatol 1988; 15(4): 593-6.

48. Salomone E, Tamburino C, Bruno G, et al. The role of endomyocardial biopsy in the diagnosis of cardiac involvement in systemic lupus erythematosus. Heart Vessels 1989; 5: 52-53.

49. Bidanin AK, Roberts JL, Schwartz MM, Lewis EJ. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 1980; 69: 849-858.

50. O´Connell JB, Henkin RE, Robinson JA, et al. Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy-proven myocarditis. Circulation 1984; 70(1): 58-62.

51. Franke C, Volkmer M, Meinertz T, Leisner B. Immunoscintigraphy using 111 In-antimyosin-antibodies in the clinical diagnosis of myocarditis. Nuklearmedizin 1992; 31(5): 182-5.

52. Yasuda T, Palacios IF, Dec GW, et al. Indium 111-monoclonal antimyosin antibody imaging in the diagnosis of acute myocarditis, Circulation 1987; 76(2): 306-11.

53. Sun Y, Ma P, Bax JJ, et al. 99mTc-MIBI myocardial perfusion imaging in myocarditis. Nucl Med Commun 2003; 24(7): 779-83.

54. Gagliardi MG, Bevilacqua M, Di Renzi P, et al. Usefulness of magnetic resonance imaging for diagnosis of acute myocarditis in infants and children, and comparison with endomyocardial biopsy. Am J Cardiol 1991; 68(10): 1089-91.

55. Matsouka H, Hamada M, Honda T, et al. Evaluation of acute myocarditis and pericarditis by Gd-DTPA enhanced magnetic resonance imaging. Eur Heart J 1994; 15: 283-84.

56. Rieker O, Mohrs O, Oberholzer K, et al. MRT des Herzens bei Verdacht auf Myokarditis. Herz 2002; 174: 1530-1536.

57. Dill T, Ekinci O, Hansel J, et al. Delayed contrast-enhanced magnetic resonance imaging for the detection of autoimmune myocarditis and long-term follow-up. J Cardiovasc Magn Reson 2005; 7(2): 521-3.

58. Been M, Thomson BJ, Smith MA, et al. Myocardial involvement in systemic lupus erythematosus detected by magnetic resonance imaging. Eur Heart J 1988; 9(11): 1250-6.

59. Singh JA, Woodard PK, Davila-Roman VG, et al. Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report. Lupus 2005; 14(2): 137-44.

60. Badui E, Garcia-Rubi D, Robles E, et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 1985; 36(7): 431-41.

61. Dubois EL, Tuffanelli DL. Clinical manifestation of systemic lupus erythematosus Computer analysis of 520 cases. JAMA 1964; 190: 104-110.

62. Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1985; 110(6): 1257-65.

63. Hejtmancik M, Wright J, Quint R, Jemmings F. The cardiovascular manifestation of systemic lupus erythematosus. Am Heart J 1964; 68: 119-30.

64. Kahl LE. The spectrum of pericardial tamponade in systemic lupus erythematosus. Report of ten patients. Arthritis Rheum 1992; 35(11): 1343-9.

65. Felker G, Boehmer J, Hruban R et al. Echocardiographic findings in fulminant and acute myocarditis. J AM Coll Cardiol 2000: 36: 227-232.

66. Law WG, Thong BY, Lian TY et al. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus 2005; 14: 827-831.

67. Sasson Z, Rasooly Y, Chow CW, et al. Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol 1992; 69(19): 1629-34.

68. Kalke S, Balakrishanan C, Mangat G, et al. Echocardiography in systemic lupus erythematosus. Lupus 1998; 7(8): 540-4.

69. Shanes JG, Ghali J, Billingham ME, et al. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. Circulation 1987; 75(2): 401-5.

70. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 1989; 64(10): 1235-45.

71. Kühl U, Lauer B, Souvatzoglu M, et al. Antimyosin scintigraphy and immunohistologic analysis of endomyocardial biopsy in patients with clinically suspected myocarditis--evidence of myocardial cell damage and inflammation in the absence of histologic signs of myocarditis. J Am Coll Cardiol 1998; 32(5): 1371-6.

72. Lagana B, Schillaci O, Tubani L, et al. Lupus carditis: evaluation with technetium-99m MIBI myocardial SPECT and heart rate variability. Angiology 1999; 50(2): 143-8.

73. Morguet AJ, Sandrock D, Stille-Siegener M, Figulla HR. Indium-111-antimyosin Fab imaging to demonstrate myocardial involvement in systemic lupus erythematosus. J Nucl Med 1995; 36(8): 1432-5.

74. Jolles PR, Tatum JL. SLE myocarditis. Detection by Ga-67 citrate scintigraphy. Clin Nucl Med 1996; 21(4): 284-6.

75. Miller S, Helber U, Kramer U, et al. Subacute myocardial infarction: assessment by STIR T2-weighted MR imaging in comparison to regional function. MAGMA 2001; 13(1): 8-14.

76. Abdel-Aty H, Zagrosek A, Schulz-Menger J, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 2004; 109(20): 2411-6.

77. Sekiguchi M, Yu ZX, Hasumi M et al. Histopathologic and ultrastructural observations of acute and convalescent myocarditis: a serial endomyocardial biopsy study. Heart Vessels Suppl 1985; 1: 143-53.

78. Adzamli IK, Jolesz FA, Bleier AR, et al. The effect of gadolinium-DTPA on tissue water compartments in slow- and fast-twith rabbit muscles. Magn Reson Med 1989; 11(2): 172-81.

79. Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26(15): 1461-74.

80. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003; 108(16): 1945-53.

81. Brigden W, Bywaters EGL, Lessof MH, Ross IP. The heart in systemic lupus erythematosus. Br Heart J 1960; 22: 1-16.

82. Toloza SM, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US corort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50(12): 3947-57.

83. Drenkard C, Villa AR, Reyes E, et al. Vasculitis in systemic lupus erythematosus. Lupus 1997; 6(3): 235-42.

84. Logar D, Kveder T, Rozman B, Dobovisek J. Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 1990; 49(8): 627-9.

85. O'Neill TW, Mahmoud A, Tooke A, et al. Is there a relationship between subclinical myocardial abnormalities, conduction defects and Ro/La antibodies in adults with systemic lupus erythematosus? Clin Exp Rheumatol 1993; 11(4): 409-12.

86. Borenstein DG, Fye WB, Arnett FC, Stevens MB. The myocarditis of systemic lupus erythematosus: association with myositis. Ann Intern Med 1978; 89: 619-24.